[go: up one dir, main page]

MX2016008258A - Celulas eucariotas novedosas y metodos para la expresion recombinante de un producto de interes. - Google Patents

Celulas eucariotas novedosas y metodos para la expresion recombinante de un producto de interes.

Info

Publication number
MX2016008258A
MX2016008258A MX2016008258A MX2016008258A MX2016008258A MX 2016008258 A MX2016008258 A MX 2016008258A MX 2016008258 A MX2016008258 A MX 2016008258A MX 2016008258 A MX2016008258 A MX 2016008258A MX 2016008258 A MX2016008258 A MX 2016008258A
Authority
MX
Mexico
Prior art keywords
interest
product
new
cells
eucariot
Prior art date
Application number
MX2016008258A
Other languages
English (en)
Other versions
MX373329B (es
Inventor
Jostock Thomas
Laux Holger
Ritter Anett
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52278688&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016008258(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2016008258A publication Critical patent/MX2016008258A/es
Publication of MX373329B publication Critical patent/MX373329B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • C07K14/4703Inhibitors; Suppressors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • C12N15/902Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells
    • C12N2510/02Cells for production
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2511/00Cells for large scale production
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente divulgación se refiere a nuevos derivados de célula huésped eucariota adecuado para la producción recombinante de un producto de interés, en el que el genoma de la célula hospedera se altera de manera que el efecto de la proteína FAM60A se altera en dicha célula, por ejemplo, reduciendo o eliminando la expresión funcional del gen FAM60A mejorando así las características de estabilidad. Además, la presente descripción proporciona tecnologías asociadas en el que dichas células hospederas que se utilizan en tecnologías recombinantes de producción.
MX2016008258A 2013-12-20 2014-12-18 Células eucariotas novedosas y métodos para la expresión recombinante de un producto de interés. MX373329B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361919340P 2013-12-20 2013-12-20
PCT/IB2014/067076 WO2015092737A1 (en) 2013-12-20 2014-12-18 Novel eukaryotic cells and methods for recombinantly expressing a product of interest

Publications (2)

Publication Number Publication Date
MX2016008258A true MX2016008258A (es) 2016-09-29
MX373329B MX373329B (es) 2020-05-21

Family

ID=52278688

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016008258A MX373329B (es) 2013-12-20 2014-12-18 Células eucariotas novedosas y métodos para la expresión recombinante de un producto de interés.

Country Status (18)

Country Link
US (2) US11242551B2 (es)
EP (2) EP3083677B1 (es)
JP (1) JP6709156B2 (es)
KR (1) KR102288232B1 (es)
CN (1) CN106029691A (es)
AU (1) AU2014369177B2 (es)
BR (1) BR112016013420A2 (es)
CA (1) CA2934412C (es)
DK (1) DK3083677T3 (es)
ES (1) ES2758505T3 (es)
IL (1) IL245856B (es)
LT (1) LT3083677T (es)
MX (1) MX373329B (es)
PL (1) PL3083677T3 (es)
PT (1) PT3083677T (es)
RU (1) RU2712507C2 (es)
SG (1) SG11201604218RA (es)
WO (1) WO2015092737A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2934411C (en) 2013-12-20 2022-05-03 Novartis Ag Novel eukaryotic cells and methods for recombinantly expressing a product of interest
EP3015475A1 (en) 2014-10-31 2016-05-04 Novartis AG Mammalian cells expressing cytomegalovirus antigens
EP3048114A1 (en) 2015-01-22 2016-07-27 Novartis AG Cytomegalovirus antigens and uses thereof
CN108018302A (zh) * 2016-10-31 2018-05-11 三生国健药业(上海)股份有限公司 一种高表达外源蛋白稳定细胞株的筛选方法
UY37758A (es) 2017-06-12 2019-01-31 Novartis Ag Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
CN107723276B (zh) * 2017-11-02 2021-08-13 上海交通大学 一种稳定高表达目标产物的细胞株的构建方法和试剂盒
US11624080B2 (en) 2017-11-28 2023-04-11 Danmarks Tekniske Universitet Glycosylation of proteins
UY38299A (es) 2018-07-18 2020-02-28 Novartis Ag Apirasas solubilizadas, métodos y usos
SG11202103334YA (en) 2018-10-26 2021-05-28 Hoffmann La Roche Multispecific antibody screening method using recombinase mediated cassette exchange
US20240409614A1 (en) 2021-11-09 2024-12-12 Danmarks Tekniske Universitet Variants of alpha-1-antitrypsin

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2585532B2 (ja) 1986-05-10 1997-02-26 三井東圧化学株式会社 動物細胞の形質転換体及びそれを得る方法並びにその形質転換体を用いてt−PAを生産する方法
JP3150340B2 (ja) 1990-11-13 2001-03-26 イムネクス コーポレイション 二機能選択可能融合遺伝子
CA2104598C (en) 1991-03-29 2003-01-07 Justus B. Cohen Methods for selection of recombinant host cells expressing high levels of a desired protein
CA2163427A1 (en) 1993-05-21 1994-12-08 Stephen D. Lupton Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
JP4031154B2 (ja) 1999-07-30 2008-01-09 独立行政法人科学技術振興機構 遺伝子増幅細胞の迅速選択法
US20060099673A1 (en) 2001-08-02 2006-05-11 Hansjorg Hauser Novel recombinant gene expression method by stop codon suppression
JP2005526517A (ja) 2002-05-22 2005-09-08 バイオジェン・アイデック・エムエイ・インコーポレイテッド 分泌性ポリペプチドの検出
WO2004035732A2 (en) 2002-08-29 2004-04-29 Five Prime Therapeutics, Inc. Human polypeptides encoded by polynucleotides and methods of their use
ES2309508T3 (es) 2003-03-11 2008-12-16 Laboratoires Serono Sa Vectores de expresion que comprenden el promotor de mcmv-ie2.
GB0324044D0 (en) * 2003-10-14 2003-11-19 Astrazeneca Ab Protein
ES2329807T3 (es) 2004-01-30 2009-12-01 Maxygen Holdings Ltd. Translectura regulada de codones de terminacion.
US20050272061A1 (en) 2004-02-19 2005-12-08 Seattle Genetics, Inc. Expression profiling in non-small cell lung cancer
IL165484A0 (en) 2004-11-30 2006-01-15 Applied Research Systems Production of proteins
US8354516B2 (en) 2006-05-17 2013-01-15 Hoffmann-La Roche Inc. Polypeptide producing cells
AU2007352346B2 (en) * 2006-10-30 2012-12-06 Eli Lilly And Company Random homozygous gene perturbation to enhance antibody production
US20080116234A1 (en) 2006-11-17 2008-05-22 3M Innovative Properties Company Ribbon curling device
JP2010517587A (ja) 2007-02-15 2010-05-27 ディーエスエム アイピー アセッツ ビー.ブイ. 関心のある化合物を生産するための組み換え宿主細胞
CN101765660B (zh) 2007-05-22 2013-10-23 巴斯夫植物科学有限公司 具有提高的环境胁迫耐受性和/或抗性和提高的生物量生产的植物细胞和植物
EP2186905B1 (en) 2007-08-07 2016-07-13 Chugai Seiyaku Kabushiki Kaisha Method of producing heterogeneous protein
US20100330572A1 (en) 2007-12-21 2010-12-30 Assaraf Yehuda G Organic compounds
US9758779B2 (en) 2008-08-28 2017-09-12 Novartis Ag Cell surface display of polypeptide isoforms by stop codon readthrough
EP2401377B1 (en) 2009-02-27 2016-05-18 Novartis AG Expression vector system comprising two selection markers
EP2430159A1 (en) 2009-05-15 2012-03-21 Boehringer Ingelheim International GmbH Improved cell lines having reduced expression of nocr and use thereof
CA2934411C (en) 2013-12-20 2022-05-03 Novartis Ag Novel eukaryotic cells and methods for recombinantly expressing a product of interest
WO2019195274A2 (en) * 2018-04-02 2019-10-10 University Of Delaware Method to alter chinese hamster ovary cell line stability
CN114381433B (zh) * 2021-12-31 2024-05-10 浙江大学 Fam60a修饰的间充质干细胞及其制备方法和应用

Also Published As

Publication number Publication date
US20170058307A1 (en) 2017-03-02
AU2014369177B2 (en) 2017-04-20
KR20160099675A (ko) 2016-08-22
CA2934412A1 (en) 2015-06-25
EP3604332A1 (en) 2020-02-05
DK3083677T3 (da) 2019-11-25
US11242551B2 (en) 2022-02-08
RU2712507C2 (ru) 2020-01-29
CN106029691A (zh) 2016-10-12
EP3083677A1 (en) 2016-10-26
CA2934412C (en) 2024-02-20
US20220325310A1 (en) 2022-10-13
PL3083677T3 (pl) 2020-03-31
IL245856B (en) 2021-06-30
LT3083677T (lt) 2019-12-10
KR102288232B1 (ko) 2021-08-10
JP2016540518A (ja) 2016-12-28
AU2014369177A1 (en) 2016-06-16
BR112016013420A2 (pt) 2017-09-26
WO2015092737A1 (en) 2015-06-25
ES2758505T3 (es) 2020-05-05
SG11201604218RA (en) 2016-07-28
PT3083677T (pt) 2019-12-02
MX373329B (es) 2020-05-21
EP3083677B1 (en) 2019-08-28
IL245856A0 (en) 2016-07-31
RU2016129278A (ru) 2018-01-25
JP6709156B2 (ja) 2020-06-10

Similar Documents

Publication Publication Date Title
MX2016008258A (es) Celulas eucariotas novedosas y metodos para la expresion recombinante de un producto de interes.
MX2020006117A (es) Integracion dirigida de acidos nucleicos.
MX366939B (es) Producción mejorada de derivados de ácidos grasos.
MY208943A (en) Taurine supplemented cell culture medium and methods of use
MX2016008249A (es) Celulas eucariotas novedosas y metodos para la expresion recombinante de un producto de interes.
BR112016025516A2 (pt) composições para controle de mosquito e usos das mesmas
BR112014026206A2 (pt) sistemas e métodos celulares para melhorar a síntese de ácidos graxos através da expressão da desidrogenase
MX2017002765A (es) Il-23a y tnf-alfa orientados y compuesto y sus usos.
AR095232A1 (es) Métodos y composiciones para el control de malezas
BR112017011542A2 (pt) produção de ácido oleico em levedura
MX2015007361A (es) Produccion mediada por la proteina portadora de acilo de los derivados de acidos grasos.
BR112016016539A2 (pt) micro-organismos recombinantes enriquecidos com carboidratos
BR112017013394A2 (pt) fabricação de proteína
BR112017011582A2 (pt) fibroblasto de embrião de galinha imortalizado, cultura de célula, métodos para preparação de um cef importalizado, para a replicação de um vetor viral aviário e para a preparação de uma vacina, e, vacina.
MX2022002057A (es) Variantes de enzima con propiedades de ester sintasa mejoradas.
MX2015012168A (es) Expansión de celulas madre adultas in vitro.
BR112016012371A2 (pt) produção microbial de aminas graxas
MX2018006373A (es) Produccion de virus en cultivos celulares.
BR112017010010A2 (pt) método para produzir 3-oxo-5-hidroxipentanoil-coa, método para biossintetizar 1,3-butanodiol, hospedeiro recombinante, produto bioderivado, produto biobaseado ou produto derivado de fermentação, retícula bioquímica de ocorrência não natural, construto de ácido nucleico ou vetor de expressão e composição
UY35438A (es) Procedimiento para preparar inhibidores de la glucosilceramida sintasa.
MX372803B (es) Polipeptidos de fusion relacionados con omega-hidroxilasa con propiedades mejoradas.
MX2018007298A (es) Variantes con mejores propiedades de polipéptidos de fusión relacionados con omega-hidroxilasa.
BR112014021326A2 (pt) célula para a expressão de protéina, método para reduzir a atividade de amidação de peptídeo em uma determinada célula, uso de uma célula
BR112018010006A2 (pt) sistema de expressão de gene, vetor, método para produção de uma célula-tronco pluripotente induzida e para tratamento de câncer, vacina, e, composição terapêutica.
BR112015022160A2 (pt) célula hospedeira geneticamente modificada, processo para degradar os ácidos nucleicos de uma célula hospedeira in vivo e/ou in situ, processo para a produção de um produto de biomassa que é livre de moléculas de ácidos nucleicos ativas, bem como uso de uma nuclease termofílica

Legal Events

Date Code Title Description
FG Grant or registration